Nurix Therapeutics Net Income

Nurix Therapeutics (NRIX) currently reports a net income of $-340M as of May 2026. That compares with $-210M in the prior-year period — down 64.6% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Nurix Therapeutics's net income history and peer comparisons.

Nurix Therapeutics's net income decreased from $-210M to $-340M — a 64.6% year-over-year decrease (period ending May 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nurix Therapeutics's net income of $-340M is lower than the Healthcare sector average of $16B. That is roughly 102.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Nurix Therapeutics reported $-340M in net income as of May 2026. That compares with $-210M in the prior-year period — down 64.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-340M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Nurix Therapeutics, and consider following NRIX for alerts when major investors trade the stock.